This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate CING, were recently guests on Benzinga's All Access.

Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer.

Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.